Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

3.90
+0.10002.63%
Post-market: 3.88-0.0200-0.51%16:47 EDT
Volume:96.67K
Turnover:377.29K
Market Cap:216.89M
PE:-2.47
High:4.07
Open:3.80
Low:3.72
Close:3.80
Loading ...

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

GlobeNewswire
·
26 Mar

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Business Wire
·
25 Mar

BRIEF-Foghorn Therapeutics Files Prospectus For Issuance & Sale Of Shares Of Up To $100 Million From Time To Time

Reuters
·
21 Mar

Foghorn Therapeutics-Files Prospectus for Issuance & Sale of Shares of up to $100 Mln From Time to Time

THOMSON REUTERS
·
21 Mar

Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy

TIPRANKS
·
08 Mar

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances

TIPRANKS
·
07 Mar

Foghorn Therapeutics Reports Progress and Financial Stability

TIPRANKS
·
07 Mar

Foghorn Therapeutics Inc. reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
07 Mar

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
07 Mar

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

GlobeNewswire
·
07 Mar

Foghorn Therapeutics Inc. expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
03 Mar

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Simply Wall St.
·
28 Feb

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Zacks
·
27 Feb

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
11 Feb

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

TipRanks
·
09 Feb

Techne (TECH) Tops Q2 Earnings and Revenue Estimates

Zacks
·
05 Feb

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Zacks
·
03 Feb

B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target

MT Newswires Live
·
30 Jan

Foghorn Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
30 Jan